Apexion Health Women's Testosterone topical gel
HORMONEWOMEN'S HEALTH

MONTHLY SUPPLY · TOPICAL GEL

WOMEN'S TESTOSTERONE

TREATMENT

Low-dose testosterone gel for energy and libido in women

SUPPORT

Low-dose topical testosterone gel restores physiological androgen levels in women experiencing hypoactive sexual desire disorder, energy decline, or mood changes attributable to testosterone deficiency — at doses calibrated to female physiology.

Shop Now

Lab-Tested · Physician-Supervised · Discreet Delivery

Apexion Health — HORMONE

TESTOSTERONE IS A WOMEN'S HORMONE TOO.

Testosterone is produced in women's ovaries and adrenal glands throughout reproductive life, declining significantly after oophorectomy and more gradually through perimenopause. Low testosterone in women is associated with hypoactive sexual desire disorder (HSDD), persistent fatigue, reduced motivation, difficulty building or maintaining lean muscle, and mood changes. Compounded low-dose testosterone gel delivers precise micro-doses calibrated to female reference ranges — far below male TRT dosing — restoring androgen activity without masculinizing effects when properly monitored.

Clinical Benefits

WOMEN'S TESTOSTERONE SUPPORTS YOUR HEALTH AT THE CELLULAR LEVEL

  1. 01.

    ADDRESSES HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)

  2. 02.

    RESTORES ENERGY AND MOTIVATION DIMINISHED BY ANDROGEN DEFICIENCY

  3. 03.

    SUPPORTS LEAN MUSCLE MAINTENANCE AND BODY COMPOSITION

  4. 04.

    IMPROVES MOOD AND COGNITIVE DRIVE

  5. 05.

    MICRO-DOSED TO FEMALE PHYSIOLOGICAL REFERENCE RANGES

  6. 06.

    PHYSICIAN-MONITORED WITH SERIAL HORMONE PANELS

Shop Now

Clinical Evidence

How It Works in the Body

01 — Dose & Efficacy

Sexual Function Benefit (Meta-Analysis)

Sexual Desire Significant improvement30%
Sexual Arousal Improved in meta-analysis25%
Personal Distress Reduced distress scores28%

Davis et al., Lancet 2019 (36 RCTs, n=8,480)

02 — Hormone Panel

Clinical Trial Outcomes (Davis 2019)

MarkerWithoutWith Treatment
Satisfying Sexual Events/4 weeks
2.5
4.2+1.7
Sexual Desire (SDS)pts
Baseline
+8 ptsModest
Personal Distress (PDDS)pts
Baseline
−7 ptsModest
Free Testosteroneng/dL
12
28+16

Consistent, modest benefit across 36 RCTs

Davis 2019 Lancet review: testosterone modestly but consistently improves sexual function including desire, arousal, orgasm. ~1.7 additional SSEs/month. No FDA-approved female T product in US — all off-label.

Davis et al., Lancet 2019; Davis et al., NEJM 2008 (APHRODITE)

03 — Protocol

Trial-Based Evidence Assessment

EvaluationBaseline
  • ›Total & free T (LC-MS/MS)
  • ›SHBG
  • ›Exclude other causes of sexual dysfunction
6-Month TrialMonths 1–6
  • ›Transdermal ~300 mcg/day
  • ›Sexual function at 3 & 6 months
  • ›Androgenic side effects screen
ContinuationMonth 6+
  • ›Continue only if clear benefit
  • ›Discontinue if no response at 6 months
  • ›Monitor T, lipids, LFTs q6 months

6-month trial; discontinue if no clear benefit

IMS 2019, NAMS 2022: 6-month therapeutic trial. Target free T in upper premenopausal range. Transdermal preferred. Long-term CV and breast safety data limited. Not for CV prevention.

All protocols physician-supervised and adjusted per individual labs.